| abstract |
The present invention relates to a highly concentrated and stable drug for subcutaneous injection, for example, a pharmaceutically active anti-CD20 antibody such as rituximab, ocrellium or HuMab < CD20 > or a mixture of such antibody molecules . In particular, the invention relates to formulations comprising an effective amount of one or more hyaluronidase enzymes for use in combination or in the form of co-formulations, in addition to an appropriate amount of anti-CD20 antibody. The formulations may also contain one or more buffering agents, such as histidine buffers, stabilizers or two or more stabilizing agents (e.g., saccharides such as alpha, alpha-trehalose dihydrate or sucrose, and optionally second stabilizing agents , A non-ionic surfactant, and an effective amount of one or more hyaluronidase enzymes. Methods of making the formulations and uses thereof are also provided. |